为期9个月的观察性Dia-Vacc研究:疫苗类型对透析与肾移植患者SARS-CoV-2免疫的影响
该观察性Dia-Vacc研究随访9个月,评估880名参与者(125名健康医务人员、595名透析患者、111名肾移植受者、49名单采患者)在2剂SARS-CoV-2 mRNA疫苗接种后8周血清转阳者的特异性细胞或/和体液免疫应答。9个月时,MP中90%、AP中86%的RBD抗体仍阳性,而DP/KTR仅55%/48%;与MP相比,DP而非KTR或AP存在RBD抗体强烈下降的风险;多因素分析显示BNT162b2 mRNA相对于1273-mRNA疫苗类型是RBD抗体强烈下降的独立危险因素。作者认为透析患者应比普通人群更早考虑加强接种。
要点
- 9个月时RBD抗体阳性率:MP 90%、AP 86%,DP 55%、KTR 48%。
- 与MP相比,DP而非KTR或AP存在RBD抗体强烈下降的风险。
- BNT162b2 mRNA相对1273-mRNA疫苗类型是RBD抗体强烈下降的独立危险因素。
核心结论
- 血清转阳的KTR随时间推移RBD值保持最低,而DP在成功的SARS-CoV-2 mRNA疫苗接种后存在RBD抗体强烈下降的特有风险,这也取决于所用疫苗类型。
- 因此,透析患者应比普通人群更早考虑加强接种。
研究设计与样本
- 观察性Dia-Vacc研究,9个月随访数据,纳入880名参与者,包括125名健康医务人员(MP)、595名透析患者(DP)、111名肾移植受者(KTR)和49名单采患者(AP),均为2剂SARS-CoV-2 mRNA疫苗接种后8周血清转阳(ELISA新发IgA或IgG抗体阳性)者。
主要发现
- 首次接种后9个月,RBD抗体仍阳性者MP为90%、AP为86%,而DP/KTR分别为55%/48%。
- 血清转阳仍阳性者AP为100%、MP为99.2%,而DP/KTR分别为86%/81%。
- 与MP相比,DP而非KTR或AP存在RBD抗体强烈下降的风险,而KTR随时间推移RBD值保持最低。
- 多因素分析显示,BNT162b2 mRNA相对于1273-mRNA疫苗类型是RBD抗体强烈下降的独立危险因素。
- 在DP组内,透析时间(仅此一项)是另一个(反向)危险因素;与体液免疫相比,T细胞免疫下降较不显著。
临床怎么用
- 作者认为,透析患者应比普通人群更早考虑加强接种。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SARS-CoV-2mRNA vaccination related seroconversion rates are reduced in dialysis and kidney transplant patients. METHODS: We evaluated nine months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 880 participants including healthy medical personnel (125-MP), dialysis patients (595-DP), kidney transplant recipients (111-KTR), and apheresis patients (49-AP) with positive seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. FINDINGS: Nine months after first vaccination, receptor binding domain (RBD) antibodies were still positive in 90 % of MP, 86 % of AP, but only 55 %/48 % of DP/KTR, respectively. Seroconversion remained positive in 100 % of AP and 99·2 % of MP, but 86 %/81 % of DP/KTR, respectively. Compared to MP, DP but not KTR or AP were at risk for a strong RBD decline, while KTR kept lowest RBD values over time. By multivariate analysis, BNT162b2mRNA versus 1273-mRNA vaccine type was an independent risk factor for a strong decline of RBD antibodies. Within the DP group, only time on dialysis was another (inverse) risk factor for the DP group. Compared to humoral immunity, T-cell immunity decline was less prominent. INTERPRETATION: While seroconverted KTR reach lowest RBD values over time, DP are at specific risk for a strong decline of RBD antibodies after successful SARS-CoV-2mRNA vaccination, which also depends on the vaccine type being used. Therefore, booster vaccinations for DP should be considered earlier compared to normal population.
引用
- Stumpf J, Anders L, Siepmann T, et al. 9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients. Vaccine. 2023. PMID: 38114410. doi:10.1016/j.vaccine.2023.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。